Advertisement
Canada markets open in 5 hours 46 minutes
  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     
  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     
  • DOW

    37,775.38
    +22.07 (+0.06%)
     
  • CAD/USD

    0.7271
    +0.0007 (+0.10%)
     
  • CRUDE OIL

    83.70
    +0.97 (+1.17%)
     
  • Bitcoin CAD

    88,768.16
    +4,830.37 (+5.75%)
     
  • CMC Crypto 200

    1,328.74
    +16.12 (+1.23%)
     
  • GOLD FUTURES

    2,403.00
    +5.00 (+0.21%)
     
  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     
  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     
  • NASDAQ futures

    17,420.75
    -126.50 (-0.72%)
     
  • VOLATILITY

    21.07
    +3.07 (+17.05%)
     
  • FTSE

    7,840.37
    -36.68 (-0.47%)
     
  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     
  • CAD/EUR

    0.6824
    +0.0003 (+0.04%)
     

Xcel Energy (XEL) Q4 Earnings Beat Estimates, Revenues Miss

Xcel Energy Inc. XEL posted fourth-quarter 2019 operating earnings of 56 cents per share, which beat the Zacks Consensus Estimate of 53 cents by 5.6%.

For 2019, the company reported earnings of $2.64, up 6.8% from $2.47 in 2018.

The upside can be attributed to higher electric margins, courtesy of favorable non-fuel riders and regulatory rate outcomes as well as natural gas margins and lower O&M expenses. However, these factors were partially offset by lower AFUDC, increased depreciation and interest expenses.

Total Revenues

Xcel Energy’s fourth-quarter revenues of $2,798 million missed the Zacks Consensus Estimate of $3,178 million by 11.9%. Revenues fell 2.8% from the prior-year quarter’s tally of $2,880 million.

Xcel Energy’s total operating revenues for 2019 was $11,529 million, down 0.06% from $11,537 million in 2018.

Xcel Energy Inc. Price, Consensus and EPS Surprise

 

Xcel Energy Inc. Price, Consensus and EPS Surprise
Xcel Energy Inc. Price, Consensus and EPS Surprise

Xcel Energy Inc. price-consensus-eps-surprise-chart | Xcel Energy Inc. Quote

ADVERTISEMENT

 

Segment Results

Electric: Revenues declined 3% to $2,231 million from $2,300 million in the last reported quarter.

Natural Gas:  Revenues fell 2.5% to $544 million from the year-ago quarter’s tally.

Other: Revenues in the segment amounted to $23 million in the quarter, up by a penny from the year-ago quarter’s figure.

Quarterly Highlights

Total operating expenses fell 7.6% year over year to $2,348 million.

Operating income in the reported quarter increased 32.7% from the prior-year quarter’s tally to $450 million.

Total interest charges and financing costs in the reported quarter rose 13.5% from the prior-year quarter’s figure to $185 million.

Looking Ahead

Xcel Energy reaffirmed 2020 earnings per share guidance in the range of $2.73-$2.83 and long-term earnings growth in the band of 5-7% from a 2019 base of $2.60 (mid-point of the original 2019 guidance range) per share. The mid-point of the current earnings guidance range is $2.78, which is in line with the Zacks Consensus Estimate for 2020 earnings.

Xcel Energy projects an annual increase in dividend rate in the range of 5-7%.

Zacks Rank

Xcel Energy carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Utility Release

NextEra Energy, Inc. NEE reported fourth-quarter 2019 adjusted earnings of $1.44 per share, which lagged the Zacks Consensus Estimate of $1.54 by 6.5%.

Upcoming Releases

Exelon Corp. EXC is slated to report fourth-quarter 2019 results on Feb 11. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is pegged at 72 cents per share.

Dominion Energy D is scheduled to report fourth-quarter 2019 results on Feb 11. The Zacks Consensus Estimate for fourth-quarter earnings is pegged at $1.16 cents per share.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Xcel Energy Inc. (XEL) : Free Stock Analysis Report
 
Exelon Corporation (EXC) : Free Stock Analysis Report
 
Dominion Energy Inc. (D) : Free Stock Analysis Report
 
NextEra Energy, Inc. (NEE) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research